Poseida Therapeutics Inc. (PSTX) News

Poseida Therapeutics Inc. (PSTX): $2.97

0.02 (+0.68%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

B

Add PSTX to Watchlist
Sign Up

Filter PSTX News Items

PSTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PSTX News Highlights

  • PSTX's 30 day story count now stands at 2.
  • Over the past 23 days, the trend for PSTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • GENE, RARE and STEM are the most mentioned tickers in articles about PSTX.

Latest PSTX News From Around the Web

Below are the latest news stories about POSEIDA THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!

William White on InvestorPlace | December 11, 2023

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma

Yahoo | December 10, 2023

Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare

The article embarks on a transformative journey through the biopharmaceutical frontier, where the listed companies stand as titans reshaping healthcare norms.

Yiannis Zourmpanos on InvestorPlace | November 17, 2023

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023.

Yahoo | November 9, 2023

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in November:

Yahoo | November 7, 2023

Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Poseida Therapeutics, Inc. (PSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 2, 2023

Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the acceptance of three poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held at the San Diego Convention Center in San Diego and virtually on December 9-12, 2023.

Yahoo | November 2, 2023

All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | October 16, 2023

Poseida Therapeutics Announces Leadership Transition

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Mark Gergen as Executive Chairman and the transition of Kristin Yarema, Ph.D., currently President, Cell Therapy, to the role of President and Chief Executive Officer, each expected to be effective January 1, 2024.

Yahoo | October 9, 2023

Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich

Are you looking to invest in biotechnology breakthroughs?

Yiannis Zourmpanos on InvestorPlace | October 3, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!